# IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

> **NCT05843448** · PHASE1 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 30 (estimated)

## Conditions studied

- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Stage 0a Bladder Cancer AJCC v8
- Stage 0is Bladder Cancer AJCC v8
- Stage I Bladder Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** PD-L1/IDO Peptide Vaccine
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05843448
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05843448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05843448, "IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05843448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*